p53 is associated with high‐risk and pinpoints TP53 missense mutations in mantle cell lymphoma

Summary Survival for patients diagnosed with mantle cell lymphoma (MCL) has improved drastically in recent years. However, patients carrying mutations in tumour protein p53 (TP53) do not benefit from modern chemotherapy‐based treatments and have poor prognosis. Thus, there is a clinical need to iden...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2020-12, Vol.191 (5), p.796-805
Hauptverfasser:	Rodrigues, Joana M., Hassan, May, Freiburghaus, Catja, Eskelund, Christian W., Geisler, Christian, Räty, Riikka, Kolstad, Arne, Sundström, Christer, Glimelius, Ingrid, Grønbæk, Kirsten, Kwiecinska, Anna, Porwit, Anna, Jerkeman, Mats, Ek, Sara
Format:	Artikel
Sprache:	eng
Schlagworte:	Cell Proliferation Chemotherapy Clinical Medicine Databases, Factual digital pathology Female Gene Expression Regulation, Neoplastic Haematological Malignancy – Biology Hematologi Hematology Humans Immunohistochemistry Klinisk medicin Lymphoma, Mantle-Cell - genetics Lymphoma, Mantle-Cell - metabolism Male Mantle cell lymphoma Medical and Health Sciences Medical prognosis Medicin och hälsovetenskap Missense mutation Mutation Mutation, Missense p53 p53 Protein Research Paper Risk Factors Sweden targeted sequencing TP53 Tumor Suppressor Protein p53 - biosynthesis Tumor Suppressor Protein p53 - genetics Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!